Gut Dysbiosis in Polycystic Ovary Syndrome
Year: 2025
Type: editorial
Abstract: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting approximately 4%–20% of women of reproductive age globally, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Out of various theories, dysbiosis of the gut has been proposed as an important factor in etiopathogenesis, which is an imbalance in the composition and function of intestinal bacteria. The gut microbiome, comprising trillions of microorganisms, regulates host metabolism, immunity, and hormonal balance. Dysbiosis in PCOS manifests as reduced microbial diversity and altered bacterial taxa, contributing to the disorder’s multifaceted symptoms.[1] Observational studies consistently demonstrate gut microbiota alterations in PCOS. Compared to healthy controls, women with PCOS exhibit reduced alpha diversity (within-sample species richness) and shifts in beta diversity (between-sample compositional differences). A hallmark is an elevated Firmicutes-to-Bacteroidetes ratio, often linked to obesity and metabolic dysfunction. Beneficial genera such as Lactobacillus, Bifidobacterium, Akkermansia, and Prevotella are depleted, whereas pro-inflammatory or opportunistic taxa such as Bacteroides, Escherichia/Shigella, Enterobacteria, and Bilophila wadsworthia are enriched.[1,2] These microbial shifts correlate with clinical markers, including elevated testosterone, body mass index (BMI), and homeostatic model assessment for insulin resistance. Fecal microbiota transplantation (FMT) studies in rodent models provide evidence of causality: transferring gut microbiota from PCOS patients to germ-free mice induces PCOS-like phenotypes, such as irregular estrous cycles, hyperandrogenism, and IR.[1] Obesity amplifies these changes, as obese PCOS patients exhibit greater reductions in anti-inflammatory bacteria and higher abundances of lipopolysaccharide (LPS)-producing Gram-negative species.[2] The mechanisms linking gut dysbiosis to PCOS are multifaceted, involving metabolic, inflammatory, and endocrine pathways. A key pathway involves reduced production of short-chain fatty acids (SCFAs) – acetate, propionate, and butyrate – due to diminished SCFA-producing bacteria (e.g., Ruminococcus and Clostridium). SCFAs, derived from bacterial fermentation of dietary fibers, activate G-protein-coupled receptors (GPR41/43), promoting secretion of glucagon-like peptide-1 (GLP-1) and peptide YY, which enhance insulin sensitivity and satiety. In PCOS, lower SCFA levels impair gut barrier integrity and glucose homeostasis, contributing to IR and obesity. Hyperinsulinemia, in turn, stimulates ovarian androgen production, exacerbating hyperandrogenism.[1] Another critical mechanism involves LPS from Gram-negative bacteria. Dysbiosis increases gut permeability (“leaky gut”), allowing LPS to enter the bloodstream, causing endotoxemia. LPS binds toll-like receptor 4, triggering nuclear Factor kappa B pathways and releasing pro-inflammatory cytokines (e.g., tumor necrosis factor-alpha and interleukin 6). This chronic low-grade inflammation worsens IR, adipose tissue dysfunction, and androgen excess by stimulating ovarian theca cell androgen synthesis.[2] Bile acid metabolism is also disrupted in PCOS-related dysbiosis. Gut bacteria express enzymes like bile salt hydrolase, converting primary bile acids to secondary forms (e.g., deoxycholic acid). Reduced abundances of beneficial bacteria decrease secondary bile acid pools, impairing activation of farnesoid X receptor and Takeda G-protein-coupled receptor 5, which regulate insulin signaling, lipid metabolism, and the hypothalamic–pituitary–ovarian axis. Dysregulated bile acids correlate with elevated androgens and disrupted folliculogenesis.[3] In addition, microbial β-glucuronidase deconjugates estrogens and androgens, facilitating their enterohepatic recirculation and contributing to hormonal imbalances.[3] The gut–brain axis further links dysbiosis to PCOS via altered secretion of gastrointestinal peptides (e.g., ghrelin and GLP-1) and vagal signaling, which influence hypothalamic gonadotropin-releasing hormone and luteinizing hormone pulses, driving ovulatory dysfunction.[1] Prenatal or early-life androgen exposure may program long-term dysbiosis, as animal models show persistent microbial shifts associated with metabolic risks.[2] Therapeutic strategies targeting gut dysbiosis offer promising avenues for PCOS management. Probiotics, such as Lactobacillus rhamnosus and Bifidobacterium lactis, restore microbial balance, improving IR, lipid profiles, and hormonal parameters after 8–12 weeks of supplementation. Prebiotics such as inulin and fructooligosaccharides promote SCFA-producing bacteria, reducing inflammation and BMI. Synbiotics, combining probiotics and prebiotics, increase sex hormone-binding globulin and alleviate hirsutism. FMT from healthy donors has normalized ovarian morphology and estrous cycles in PCOS animal models.[1,2] Conventional treatments such as metformin enhance beneficial bacteria (e.g., Akkermansia muciniphila), whereas herbal compounds, such as berberine and quercetin, modulate microbiota to mitigate IR and inflammation.[2] Dietary interventions, particularly plant-based diets rich in fiber, boost Lactobacillus and reduce Bacteroides, offering nonpharmacological options. However, personalized approaches are essential, as microbiota profiles vary widely. Ongoing clinical trials are exploring precision probiotics and postbiotics (e.g., SCFA supplements) to optimize outcomes.[1,2] In India, where PCOS prevalence is high (10%–22% by Rotterdam criteria), studies reveal unique microbiome profiles. A study on drug-naive Kashmiri women with PCOS found enriched Bifidobacterium, Collinsella, and Paraprevotella, correlating with elevated fasting glucose, obesity measures, and alkaline phosphatase levels. Unlike global trends of reduced diversity, these women showed a higher Shannon index, possibly influenced by dietary patterns, genetic factors (e.g., lactose intolerance favoring Bifidobacterium), and regional insulin resistance profiles. Elevated β-glucuronidase and β-glucosidase activities in PCOS stool samples, positively correlating with estradiol levels and suggesting microbial contributions to hormone recirculation and hyperandrogenism.[3] There is a need for ethnicity-specific microbiome research in India to address environmental and genetic influences on PCOS dysbiosis. In conclusion, gut microbiota dysbiosis is a central contributor to PCOS pathogenesis, driving metabolic, inflammatory, and hormonal imbalances. Targeting the microbiome through probiotics, prebiotics, FMT, and dietary interventions offers novel therapeutic strategies with minimal side effects. Future research should prioritize longitudinal studies, metagenomic analyses, and randomized controlled trials to establish causality and optimize interventions, particularly in diverse populations.
Source: Journal of Mid-life Health
Authors: Ruchika Garg, Atul Munshi
Institution: Sarojini Naidu Medical College
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: polycystic ovary syndrome, gut dysbiosis, gut microbiota, Firmicutes/Bacteroidetes ratio, short-chain fatty acids, insulin resistance, hyperandrogenism, obesity, inflammation, lipopolysaccharide, glucagon-like peptide-1, peptide YY, fecal microbiota transplantation, Akkermansia, Lactobacillus, Bifidobacterium, Prevotella, Ruminococcus, Clostridium
Open Access status: diamond
OpenAlex ID: W4417130622
